Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2511733123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Laura Antonucci und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, La Jolla, C…. Hauptthemen laut MEDLINE: NAD(P)H Dehydrogenase (Quinone), NF-E2-Related Factor 2, Carcinoma, Pancreatic Ductal, Prodrugs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Activation of transcription factor NRF2 in pancreatic ductal adenocarcinoma (PDAC) promotes aggressive tumor phenotype and protection from therapy-induced oxidative stress. We postulated that NRF2 high PDAC can be selectively targeted by C29h, a prodrug that is activated by the NRF2-induced enzyme NAD(P)H:quinone oxidoreductase-1 (NQO1), which is elevated in human pancreatic tumors. Initial evaluations of C29h alone or together with the standard-of-care chemotherapeutic drug gemcitabine were conducted on NQO1 high human and mouse PDAC cell lines and patient-derived organoids. As PDAC is enriched in collagen-containing extracellular matrix (ECM) that activates NRF2 and induces NQO1 expression, we examined the ECM effect on the response to C29h, as well as in vivo tumor control in IKKα-deficient Kras G12D /Ikkα ΔPEC mice in which NRF2 is strongly activated, immunocompromised Nu/Nu mice orthotopically transplanted with human PDAC cells and C57BL/6n and NOD/SCID mice transplanted with mouse PDAC. C29h led to NQO1-dependent killing of human and mouse PDAC cell lines and organoids and acted additively with gemcitabine. Furthermore, ECM-plated PDAC cells were more susceptible to C29h cytotoxicity than cells grown on plastic. Importantly, C29h treatment induced tumor regression and increased the survival of PDAC-bearing mice and optimal C29h-induced tumor regression was dependent on CD8 + T lymphocytes whose tumoral recruitment was enhanced by drug treatment. This study supports the use of C29h alone or as part of a drug combination as an effective and promising strategy for selective eradication of NRF2 high PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, La Jolla, CA 92093.
- Department of Pathology, Laboratory of Gene Regulation and Signal Transduction, University of California San Diego School of Medicine, La Jolla, CA 92093.
- Department of Oncology, Zhongda Hospital, Southeast University, Nanjing 210009, China.
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92037.
- Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016.
- Department of Pathology, Jonsson Cancer Center, University of California Los Angeles David Geffen School of Medicine Los Angeles, CA 90095.
ORCID-Profile: Laura Antonucci, Kosuke Watari, David W Dawson, Michael Karin
Förderung
- NCI NIH HHS
Zitieren
APA
Antonucci, L., Watari, K., Feng, Y., Qi, J., Zhu, M., Wang, T., Ng, I., Vucic, E. A., Riahi, I., Huang, L., Hosseini, M., Mose, E., French, R., Weitz, J., Bar-Sagi, D., Dawson, D. W., Sun, B., Tiriac, H., Xu, J., …, & Karin, M. (2026). Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2511733123
Vancouver
Antonucci L, Watari K, Feng Y, Qi J, Zhu M, Wang T, et al. Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2511733123
BibTeX
@article{Antonucci2026,
author = {Antonucci, Laura and Watari, Kosuke and Feng, Yechen and Qi, Jingjing and Zhu, Mandy and Wang, Tingya and Ng, Isabella and Vucic, Emily A and Riahi, Irene and Huang, Li and Hosseini, Mojgan and Mose, Evangeline and French, Randall and Weitz, Jonathan and Bar-Sagi, Dafna and Dawson, David W and Sun, Beicheng and Tiriac, Herve and Xu, Jinyi and Xu, Shengtao and Lowy, Andrew M and Karin, Michael},
title = {Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2511733123}
}
EUVIMED